What does SBK Pharma do?

SBK Pharma is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 21 February 2022, 1 establishment.

What is the address of SBK Pharma?

The registered office of SBK Pharma is located at Route de Ster 3, 4970 Stavelot.

Is SBK Pharma still active?

Yes. According to the CBE (30 October 2026) SBK Pharma is active, legal situation “Normale toestand”, started on 21 February 2022.

Is SBK Pharma registered on Peppol?

Yes, SBK Pharma is registered on the Peppol network with ID 0208:0782437533.

What is the enterprise number of SBK Pharma?

The enterprise number of SBK Pharma is BE0782437533.

When was SBK Pharma founded?

SBK Pharma was founded on 21 February 2022.

Who are the directors of SBK Pharma?

According to the 2025 annual accounts, the directors of SBK Pharma are: MONIQUE BECHET.

Is SBK Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 21 February 2022; 3 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did SBK Pharma make in 2025?

SBK Pharma posted a profit after taxes of € 8,967 in financial year 2025.

What is the revenue of SBK Pharma?

As a small company, SBK Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 14,431.

SBK Pharma (Private Limited) - Stavelot - BE0782437533

Dossier SBK Pharma, printed on 30 October 2026 from databakkes.be/en/0782437533/sbk-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 3 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

SBK Pharma from Stavelot, company number BE0782437533, closed financial year 2025 with a result of € 8,967 after tax. For that financial year SBK Pharma recorded a gross margin of € 14,431 and equity of € 43,628. Compared with financial year 2024, the result moved from € 13,946 to € 8,967. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.

What it is worth Growing

€ 43,628

▲ 26% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 8,967

▼ 36% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1,063

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 37,628.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 96,757

▼ 23% vs 2024

€ 29,026 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 5,137

▼ 22% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 29,984 Gross margin 2023: € 29,984 First fiscal year in the series	€ 20,697 Gross margin 2024: € 20,697 ▼ 31% vs 2023 (€ 29,984) Unfavourable step	€ 14,431 Gross margin 2025: € 14,431 ▼ 30% vs 2024 (€ 20,697) Unfavourable step	▼ 30%
Profit after taxes	€ 14,714 Profit after taxes 2023: € 14,714 First fiscal year in the series	€ 13,946 Profit after taxes 2024: € 13,946 ▼ 5% vs 2023 (€ 14,714) Unfavourable step	€ 8,967 Profit after taxes 2025: € 8,967 ▼ 36% vs 2024 (€ 13,946) Unfavourable step	▼ 36%
Equity	€ 20,714 Equity 2023: € 20,714 First fiscal year in the series	€ 34,661 Equity 2024: € 34,661 ▲ 67% vs 2023 (€ 20,714) Favourable step	€ 43,628 Equity 2025: € 43,628 ▲ 26% vs 2024 (€ 34,661) Favourable step	▲ 26%
Total debts	€ 197,517 Total debts 2023: € 197,517 First fiscal year in the series	€ 219,739 Total debts 2024: € 219,739 ▲ 11% vs 2023 (€ 197,517) Unfavourable step	€ 212,876 Total debts 2025: € 212,876 ▼ 3% vs 2024 (€ 219,739) Favourable step	▼ 3%
Cash	€ 8,232 Cash 2023: € 8,232 First fiscal year in the series	€ 0 Cash 2024: € 0 ▼ 100% vs 2023 (€ 8,232) Unfavourable step	€ 1,063 Cash 2025: € 1,063 Unchanged (€ 0) Favourable step
Retained profit	€ 14,714 Retained profit 2023: € 14,714 First fiscal year in the series	€ 28,661 Retained profit 2024: € 28,661 ▲ 95% vs 2023 (€ 14,714) Favourable step	€ 37,628 Retained profit 2025: € 37,628 ▲ 31% vs 2024 (€ 28,661) Favourable step	▲ 31%
Bank debt	€ 160,347 Bank debt 2023: € 160,347 First fiscal year in the series	€ 125,141 Bank debt 2024: € 125,141 ▼ 22% vs 2023 (€ 160,347) Favourable step	€ 96,757 Bank debt 2025: € 96,757 ▼ 23% vs 2024 (€ 125,141) Favourable step	▼ 23%
Balance sheet total	€ 218,232 Balance sheet total 2023: € 218,232 First fiscal year in the series	€ 254,400 Balance sheet total 2024: € 254,400 ▲ 17% vs 2023 (€ 218,232) Unchanged	€ 256,504 Balance sheet total 2025: € 256,504 ▲ 1% vs 2024 (€ 254,400) Unchanged	▲ 1%

Key figures of SBK Pharma, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to SBK Pharma?

What happened at SBK Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 16, 2026 New annual accounts for financial year 2025: profit of € 8,967 (▼ 36% vs 2024). Source: NBB ↗
Mar 15, 2022 New establishment in Stavelot. KBO
2022 MONIQUE BECHET became a director. NBB
Feb 21, 2022 Start of the company according to the CBE. KBO

In short

From € 14,714 profit in 2023 to € 8,967 profit in 2025.

Paid € 11,726 in corporate taxes since 2023.

Best year ever: 2023, with € 14,714 profit.

Original PDFs at the National Bank ↗

Management

MONIQUE BECHET

SBK Pharma

PHARMACONSEIL 100%

Behind SBK Pharma is MONIQUE BECHET. It owns 100% of PHARMACONSEIL itself.

Directors

According to the 2025 annual accounts

MONIQUE BECHET

Director

Also active at: PharmaConseil

since 2022

Establishments

Establishment units

Physical locations of this company

Registered office

Route de Ster 3

4970 Stavelot

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0782.437.533

VAT number

BE 0782.437.533

Registered office

Route de Ster 3, 4970 Stavelot

Names & denominations

SBK Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

21 February 2022

Peppol

Active · Active since 1 Oct 2025

Activities · NACE

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

SBK Pharma

Warning lights

Financials

What happened to SBK Pharma?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions